Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revefenacin in Acute Respiratory Insufficiency in COPD
NCT04315558Phase 2Completed
- Sponsor
- University of California, Los Angeles
- Start
- Nov 2020
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of revefenacin in chronic obstructive pulmonary disease (COPD), acute respiratory failure (ARF), sponsored by University of California, Los Angeles. Started Nov 2020; status: completed.
02
Drugs
revefenacin
03
Conditions
chronic obstructive pulmonary disease (COPD)acute respiratory failure (ARF)
Beyond the preview
Go deeper on NCT04315558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04315558.